glp-1 news today pharma The next phase of the obesity drug race Big Pharma is lying to

A 2026 review in the American Journal of Sports Medicine emphasizes that despite popularity, "significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients." Only a single human case series exists for BPC-157 (for knee pain), with significant methodological flaws and no controls

Online Medical Intake Patients complete an online health questionnaire covering: Height, weight, and BMI Medical and family history Current medications Prior weight-loss attempts Lifestyle and nutrition habits This helps determine whether GLP-1 therapy may be appropriate

More side effects

Good stuff, no doubt

Furthermore, adverse events were similar across all groups, with treatment-emergent adverse events being mild or moderate, and no severe adverse events were reported